Healthcare

AstraZeneca and Oracle team up on AI to find patients for drug trials

AstraZeneca and Oracle plan to use AI and anonymized health data to find trial candidates, starting with uncontrolled-hypertension patients in Abu Dhabi alongside M42.

AstraZeneca and Oracle are using AI and anonymized patient health data to identify potential clinical-trial participants more quickly. Their first project is planned for Abu Dhabi in partnership with M42, where doctors will look for patients with uncontrolled high blood pressure, support them with guideline-based treatment, and seek to enrol more eligible patients in trials. AstraZeneca brings expertise in drug science, clinical trials, and regulation, while Oracle contributes cloud infrastructure, AI tools, and health-data capabilities. The companies also plan projects in the United States, Middle East, and Europe covering cancer, heart and kidney disease, respiratory and immune conditions, and rare diseases. The practical healthcare application is automated or assisted patient matching: instead of relying only on manual chart review, AI can help care teams find relevant patients within health records. The initiative could make trials faster and broaden patient access, although the source describes an announced collaboration and planned programs rather than results from completed studies.

Original source: The Next Web

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI